| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2002 | US20020025919 Antiviral linear polymers |
| 02/28/2002 | US20020025918 Polypeptides |
| 02/28/2002 | US20020025578 Intensified expression of nucleotide sequences in mammal; administer nucleic acids to mammal, transfect nucleotide sequence using voltage, monitor mammal for gene expression |
| 02/28/2002 | US20020025577 Eukaryotic gene expression cassette and uses thereof |
| 02/28/2002 | US20020025570 Peptides; for use as tools in human therapeutics and diagnostic testing |
| 02/28/2002 | US20020025566 From dipeptides |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | US20020025557 32447, a novel human acyltransferase and uses thereof |
| 02/28/2002 | US20020025556 Stable factor VIII / vWF-complex |
| 02/28/2002 | US20020025555 Nucleotide sequences coding protein g-protein receptor; for use in diagnosis, evaluation and treatment of tumors, infections and inflammation |
| 02/28/2002 | US20020025553 Nucleotide sequences which code preferential polypeptide for use diagnosis, prevention and treatment of cancer, ulcers, psoriasis, nervous system, liver, kidney and vision defects; wound healing agents |
| 02/28/2002 | US20020025550 Methods for producing highly phosphorylated lysosomal hydrolases |
| 02/28/2002 | US20020025543 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 02/28/2002 | US20020025516 Nrde |
| 02/28/2002 | US20020025513 Antigen/antibody specificity exchanger |
| 02/28/2002 | US20020025343 For infusing into human patients |
| 02/28/2002 | US20020025327 Use of neurotoxin therapy for treatment of urologic and related disorders |
| 02/28/2002 | US20020025321 Composition for the prevention and/or treatment of atherosclerosis |
| 02/28/2002 | US20020025316 For promoting the healing of wounds or fibrotic disorders with reduced scarring |
| 02/28/2002 | US20020025307 Gene therapy, testing |
| 02/28/2002 | US20020025306 Providing a source of a glucoincretin that increases the responsiveness of the cell to glucose |
| 02/28/2002 | US20020025304 Novel interferon for the treatment of multiple sclerosis |
| 02/28/2002 | US20020025303 Cosmetic and/or dermatological composition containing a derivative of methylated silanol and a derivative of hydrolysed plant protein |
| 02/28/2002 | DE10040700A1 Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung Salts of biologically active peptides, their preparation and use |
| 02/28/2002 | DE10040105A1 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften Peptide and peptidomimetic derivatives having integrin inhibitor properties |
| 02/28/2002 | DE10040103A1 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften II Peptide and peptide derivatives with integrin inhibitor properties II |
| 02/28/2002 | CA2740815A1 New uses for amino acid anticonvulsants |
| 02/28/2002 | CA2420550A1 Peptide with effects on cerebral health |
| 02/28/2002 | CA2420543A1 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/28/2002 | CA2420499A1 Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide |
| 02/28/2002 | CA2420482A1 Progression suppressed gene 13 (psgen 13) and uses thereof |
| 02/28/2002 | CA2420393A1 Bacterial strains, genes and enzymes for control of bacterial diseases by quenching quorum-sensing signals |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420261A1 Genes and proteins, and their uses |
| 02/28/2002 | CA2420257A1 Identification of a cam-kinase ii inhibitor |
| 02/28/2002 | CA2420234A1 Method of administering fimh protein as a vaccine for urinary tract infections |
| 02/28/2002 | CA2420194A1 Use of a porous carrier |
| 02/28/2002 | CA2420193A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420101A1 Kidney-specific protein |
| 02/28/2002 | CA2420087A1 Cripto tumour polypeptide |
| 02/28/2002 | CA2420086A1 Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 02/28/2002 | CA2420071A1 Process for the preparation of neutrophil inhibitory factor |
| 02/28/2002 | CA2420051A1 Pharmaceutical composition comprising trkaig2 for use in the prevention and/or treatment of cancer |
| 02/28/2002 | CA2419981A1 Coaster, a human coactivator of steroid receptors |
| 02/28/2002 | CA2419919A1 Novel imidazoline receptor homologs |
| 02/28/2002 | CA2419915A1 New sequences |
| 02/28/2002 | CA2419870A1 Sh2 domain binding inhibitors |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419454A1 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | CA2419306A1 23 human secreted proteins |
| 02/28/2002 | CA2419284A1 Prna chimera |
| 02/28/2002 | CA2419274A1 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | CA2418680A1 11 human secreted proteins |
| 02/28/2002 | CA2418474A1 21 human secreted proteins |
| 02/28/2002 | CA2418461A1 Method and compositions for promoting osteogenesis |
| 02/28/2002 | CA2418006A1 Binding polypeptides for b lymphocyte stimulator protein (blys) |
| 02/28/2002 | CA2417787A1 Lipid metabolism enzymes |
| 02/28/2002 | CA2417186A1 Microtubule-associated proteins and tubulins |
| 02/28/2002 | CA2415791A1 Treatment of wounds |
| 02/28/2002 | CA2388061A1 Diagnosis and treatment of cardiovascular conditions |
| 02/27/2002 | EP1182255A1 Genes involved in immune related responses observed with asthma |
| 02/27/2002 | EP1182211A1 Chemokine-like factors having cell chemokinesis function and proliferation-stimulating activity |
| 02/27/2002 | EP1182209A2 A method for extraction and purification of cartilage type proteoglycan |
| 02/27/2002 | EP1182208A2 Composition for DNA transfection |
| 02/27/2002 | EP1182207A2 Non-covalent inhibitors of urokinase and blood vessel formation |
| 02/27/2002 | EP1181929A2 Method of potentiating an immune response and compositions therefor |
| 02/27/2002 | EP1181555A1 Cancer treatment with endothelin receptor antagonists |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181382A2 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 02/27/2002 | EP1181376A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 02/27/2002 | EP1181369A1 Four-helical bundle protein zsig81 |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181366A1 Mammalian receptor proteins; related reagents and methods |
| 02/27/2002 | EP1181364A1 Lipid metabolism transcription factor |
| 02/27/2002 | EP1181363A1 Recombinant human mannan-binding lectin |
| 02/27/2002 | EP1181362A1 Methods and reagents for inhibiting angiogenesis |
| 02/27/2002 | EP1181358A2 Methods and materials for generating sh3 domains with tailored binding properties |
| 02/27/2002 | EP1181352A1 Versican and epithelial-mesenchymal interaction |
| 02/27/2002 | EP1181320A2 Somatic transgene immunization and related methods |
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181314A1 Polyepitopic proteinic fragments of the hiv nef protein, production and use thereof in vaccinations |
| 02/27/2002 | EP1181313A2 Peptides for vaccinating against human cmv |
| 02/27/2002 | EP1181312A1 Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
| 02/27/2002 | EP1181310A1 Chemokine receptor ccr3 antagonists |
| 02/27/2002 | EP1181309A1 Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b) |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181066A1 Device and method for infusion of small molecule insulin mimetic materials |
| 02/27/2002 | EP1181057A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 02/27/2002 | EP1181056A1 Lim mineralization protein splice variants |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181052A1 Protein a based binding domains with desirable activities |
| 02/27/2002 | EP1181050A1 Methods for preventing reactivation of latent virus and controlling virus replication |
| 02/27/2002 | EP1181049A1 Cardioprotective composition comprising ceruloplasmin and uses thereof |
| 02/27/2002 | EP1181048A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor |
| 02/27/2002 | EP1181047A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |